2011
DOI: 10.1093/annonc/mdr371
|View full text |Cite
|
Sign up to set email alerts
|

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
166
0
9

Year Published

2012
2012
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 240 publications
(176 citation statements)
references
References 88 publications
1
166
0
9
Order By: Relevance
“…IHC analysis enables to identify those cell receptors using antibodies that specifically bind with antigens present in the tissue samples and this antibody-antigen binding can be detected usually by chemical or, enzymatic staining. 38,39 However, IHC analysis facility is very poor in Bangladesh thus presenting a poor diagnosis condition for TNBC in Bangladesh leading to patients having inappropriate treatment regimen in most cases.…”
Section: Tnbc Diagnosismentioning
confidence: 99%
“…IHC analysis enables to identify those cell receptors using antibodies that specifically bind with antigens present in the tissue samples and this antibody-antigen binding can be detected usually by chemical or, enzymatic staining. 38,39 However, IHC analysis facility is very poor in Bangladesh thus presenting a poor diagnosis condition for TNBC in Bangladesh leading to patients having inappropriate treatment regimen in most cases.…”
Section: Tnbc Diagnosismentioning
confidence: 99%
“…According to the AJCC/UICC TNM system's latest edition, the College of American Pathologists (2009) and the ESMO guidelines, only the largest tumor focus should be selected for classification, grading, and staging (35,36,42,43). Clinical decisions in systemic adjuvant therapy for breast cancer are presently based on morphological criteria of the largest tumor focus, ignoring those of the smaller simultaneous cancers even though the heterogeneity of individual foci in multiple carcinomas has not been widely studied (44)(45)(46).…”
Section: Morphological Profilementioning
confidence: 99%
“…International therapeutic guides recommend adjuvant endocrine therapy (Tamoxifen) in patients with breast carcinoma in which the tumor expresses estrogen receptors (ERs) and/or progesterone receptors (PRs), as well as anti-human epidermal growth factor receptor 2 (HER2) therapy (Trastuzumab) in HER2-positive cases (43,44,45,48). An increased proliferative index (Ki-67), a high histological grade, and ER/PR negativity are factors that indicate the use of chemotherapy (43,46).…”
Section: Molecular Profilementioning
confidence: 99%
“…As a result, there has been much debate regarding the timing of mastectomy in patients requiring radiotherapy. Most guidelines that address the timing of adjuvant radiotherapy recommend that breast reconstruction be delayed, or at least, discussed in a multidisciplinary setting (22,24,27 (63,64). A prospective study comparing timing of radiotherapy on permanent implants versus on tissue expanders (all two-stage immediate with subpectoral temporary expanders and permanent implants) found that the rate of failure (ie, removal of the implant, leaving the chest wall flat or change to a flap-based technique) was significantly higher when radiotherapy was delivered at the tissue expander stage rather than at the permanent implant stage (40% versus 6.4%; P<0.0001).…”
Section: What Is the Appropriate Timing Of Breast Reconstruction?mentioning
confidence: 99%